1
|
Fishbein I, Guerrero DT, Alferiev IS, Foster JB, Minutolo NG, Chorny M, Monteys AM, Driesbaugh KH, Nagaswami C, Levy RJ. Stent-based delivery of adeno-associated viral vectors with sustained vascular transduction and iNOS-mediated inhibition of in-stent restenosis. Gene Ther 2017; 24:717-726. [PMID: 28832561 PMCID: PMC5709213 DOI: 10.1038/gt.2017.82] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Revised: 07/31/2017] [Accepted: 08/10/2017] [Indexed: 01/05/2023]
Abstract
In-stent restenosis remains an important clinical problem in the era of drug eluting stents. Development of clinical gene therapy protocols for the prevention and treatment of in-stent restenosis is hampered by the lack of adequate local delivery systems. Herein we describe a novel stent-based gene delivery platform capable of providing local arterial gene transfer with adeno-associated viral (AAV) vectors. This system exploits the natural affinity of protein G (PrG) to bind to the Fc region of mammalian IgG, making PrG a universal adaptor for surface immobilization of vector-capturing antibodies (Ab). Our results: 1) demonstrate the feasibility of reversible immobilization of AAV2 vectors using vector tethering by AAV2-specific Ab appended to the stent surface through covalently attached PrG, 2) show sustained release kinetics of PrG/Ab-immobilized AAV2 vector particles into simulated physiological medium in vitro and site-specific transduction of cultured cells, 3) provide evidence of long-term (12 weeks) arterial expression of luciferase with PrG/Ab-tethered AAV2Luc, and 4) show anti-proliferative activity and anti-restenotic efficacy of stent-immobilized AAV2iNOS in the rat carotid artery model of stent angioplasty.
Collapse
Affiliation(s)
- I Fishbein
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA.,The Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
| | - D T Guerrero
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - I S Alferiev
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA.,The Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
| | - J B Foster
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - N G Minutolo
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA.,The Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
| | - M Chorny
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA.,The Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
| | - A M Monteys
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - K H Driesbaugh
- The Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
| | - C Nagaswami
- The Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
| | - R J Levy
- The Children's Hospital of Philadelphia, Philadelphia, PA, USA.,The Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
2
|
Atta HM. Gene therapy for liver regeneration: experimental studies and prospects for clinical trials. World J Gastroenterol 2010; 16:4019-30. [PMID: 20731015 PMCID: PMC2928455 DOI: 10.3748/wjg.v16.i32.4019] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2009] [Revised: 03/03/2010] [Accepted: 03/10/2010] [Indexed: 02/06/2023] Open
Abstract
The liver is an exceptional organ, not only because of its unique anatomical and physiological characteristics, but also because of its unlimited regenerative capacity. Unfolding of the molecular mechanisms that govern liver regeneration has allowed researchers to exploit them to augment liver regeneration. Dramatic progress in the field, however, was made by the introduction of the powerful tool of gene therapy. Transfer of genetic materials, such as hepatocyte growth factor, using both viral and non-viral vectors has proved to be successful in augmenting liver regeneration in various animal models. For future clinical studies, ongoing research aims at eliminating toxicity of viral vectors and increasing transduction efficiency of non-viral vectors, which are the main drawbacks of these systems. Another goal of current research is to develop gene therapy that targets specific liver cells using receptors that are unique to and highly expressed by different liver cell types. The outcome of such investigations will, undoubtedly, pave the way for future successful clinical trials.
Collapse
|